Why is this important? The behavioral effects of CBD on people is still widely being studied. It is, however, known as a relatively safe treatment for chronic ailments like pain and anxiety. What’s more, CBD is accepted and used in many regions of the world where illicit drugs are strictly prohibited. Even other cannabis-related products are deemed illegal if they contain any amount of THC.
The study showed that doses of up to 1500 mg per day had no effect on any people while they were driving. While these effects of CBD were expected, scientific research studies offer another level of legitimacy for the industry. It’s why investors can be bullish on the CBD industry, while still being reserved about cannabis legalization, especially in the US.
As the country awaits the decision from the Senate on federal legalization as the MORE Act vote makes its way through the various levels of the US government, many investors have already turned their attention to CBD. Companies like Tilray (NASDAQ:TLRY), Jazz Pharmaceuticals (NASDAQ:JAZZ), Charlotte’s Web (OTC:CWBHF), and Endexx (OTC:EDXC) are all vying for market share of the CBD space.
Companies like Endexx are reaping the rewards of a broader awareness of CBD treatments and products. Endexx recently added its products to over 2,800 mass retail stores across the US, and is rapidly finding popularity in the red-hot pet CBD treatment market. Endexx reported a year over year sales increase of 73% in the first quarter of 2022.
$TLRY $JAZZ $CWBHF $EDXC